Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study
ConclusionsThese findings suggest that ramucirumab monotherapy has clinical activity and a manageable safety profile in Japanese patients with gastric cancer after disease progression following first-line chemotherapy.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
More News: Adenocarcinoma | Bleeding | Cancer | Cancer & Oncology | Chemotherapy | Gastric (Stomach) Cancer | Gastroenterology | Japan Health | Proteinuria | Study